Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...

Now that a window has finally opened on Wall Street for biotech IPOs, a lineup of drug developers are taking their chances and jumping through. The latest to join the queue is Ambit Biosciences, which ...

Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...